Study tests immunotherapy plus electroporation for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study looks at whether adding immunotherapy to a procedure called irreversible electroporation can help treat stage III pancreatic cancer. You might be eligible if you have measurable tumors and can safely undergo the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have stage III pancreatic cancer
- Have a tumor doctors can measure on scans (measurable tumor)
- Have kidney function test showing eGFR above 60 (a blood test measure of kidney filtering)
- Be willing and able to follow the study plan and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a combination of chemotherapy and a procedure called irreversible electroporation (IRE) for people with stage III pancreatic cancer. It may help shrink or control tumors, and also studies safety in this group.
This study looks at people with advanced pancreatic cancer who have already been treated with a procedure called irreversible electroporation (IRE), which uses electric pulses to kill cancer cells, sometimes along with immunotherapy drugs. The goal is to learn more about how well this combination works and how safe it is.
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
This trial tests a new type of vaccine (called ONVAX-01) combined with an immunotherapy drug and chemotherapy for advanced pancreatic cancer. The goal is to see if this combination can help your immune system fight the cancer more effectively than the usual treatments alone.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a procedure that uses sound waves to heat and destroy part of the tumor, combined with an immunotherapy drug called pembrolizumab (Keytruda) that helps your immune system fight the cancer. It is for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.